Investors

Mauna Kea Technologies
Stock Information

Mauna Kea Technologies
Stock Information

Stay up to date on all our investor news

0,0825€

Last updated
21/05/2025 - 09:11

'

-0,60%

€10.5M

Sales in 2023

+42%

Sales growth in 2023

excluding exchange rates

+52%

PPU growth in 2023

excluding exchange rates

Events and
Presentations

Financial
Results

Governance

News

Mauna Kea Technologies announces the availability of preparatory documents for the Combined General Meeting of June 5, 2025 and the instructions for participation 

Mauna Kea Technologies announces the availability of preparatory documents for the Combined General Meeting of June 5, 2025 and the instructions for participation 

Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week® 2025 

Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week® 2025 

Publication of the 2024 Annual Financial Report 

Publication of the 2024 Annual Financial Report 

No results found.

Shareholding Structure

A long term vision shared by major strategic shareholders: Johnson & Johnson (NYSE: JNJ) and Telix Pharmaceuticals (ASX : TLX)

Stock Information

IDENTIFICATION CODES

ISIN : FR0010609263

Ticker : ALMKT

ANALYST COVERAGE

GILBERT DUPONT

Guillaume Cuvillier

EUROLAND CORPORATE
EUROLAND CORPORATE

Raphaël Génin

STATUTORY AUDITORS

• EY and Others, represented by Mr Franck SEBAG, 1-2 place des Saisons, 92400 Courbevoie- Paris La Défense, France

• Exco Socodec, represented by Monsieur Olivier Gallezot, 51, Avenue Françoise Giroud, Parc Valmy, 21066 Dijon